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Abstract
The Warburg effect - a classical hallmark of cancer metabolism - is a counter-intuitive phenomenon in which rapidly
proliferating cancer cells resort to inefficient ATP production via glycolysis leading to lactate secretion, instead of relying
primarily on more efficient energy production through mitochondrial oxidative phosphorylation, as most normal cells do.
The causes for the Warburg effect have remained a subject of considerable controversy since its discovery over 80 years
ago, with several competing hypotheses. Here, utilizing a genome-scale human metabolic network model accounting for
stoichiometric and enzyme solvent capacity considerations, we show that the Warburg effect is a direct consequence of the
metabolic adaptation of cancer cells to increase biomass production rate. The analysis is shown to accurately capture a
three phase metabolic behavior that is observed experimentally during oncogenic progression, as well as a prominent
characteristic of cancer cells involving their preference for glutamine uptake over other amino acids.
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Introduction
The Warburg effect, a phenomenon discovered by Otto
Warburg in 1924, reflects a shift to an inefficient metabolism in
cancer cells, in which an increase in the inefficient production of
adenosine 59-triphosphate (ATP) via glycolysis leads to the
secretion of non-oxidized carbons in the form of lactate, even in
the presence of oxygen (termed aerobic glycolysis) [1,2]. Specifically,
aerobic glycolysis allows the production of only 2 ATP molecules
per one glucose molecule, whereas oxidative phosphorylation
permits the generation of 32 ATP molecules per one molecule of
glucose [3]. Nevertheless, the importance of aerobic glycolysis to
cancer cells has been experimentally demonstrated [4,5].
Over the years, several hypotheses were raised regarding the
potential cause of the Warburg effect: (i) Defective mitochondrion
hypothesis – suggesting that cancer cells have defective mitochondria
and hence rely on glycolysis [6], however subsequent research
revealed that mitochondrial function is not impaired in most cancer
cells [7,8]. (ii) Hypoxia– suggesting that tumor hypoxia selects for cells
dependent on anaerobic metabolism [9], but previous studies have
shown that cancer cells already resort to aerobic glycolysis before
exposure to hypoxic conditions [10,11]. (iii) Avoiding ROS-mediated
DNA damage – it was suggested that reducing oxidative phosphor-
ylation in proliferating cells due to the Warburg shift reduces ROS
andhence protectscellsfromDNAdamageand subsequentapoptosis
[12]. (iv) A game theoretical approach suggesting that the Warburg
effect occurs as glycolysis provides higher ATP production rate than
oxidative phosphorylation [13,14,15]. (v) An approach suggesting
that a trade-off between the enzyme-synthesis costs and the ATP
production yields of the different pathways that catabolize carbon
sources may cause the Warburg effect: the high-yield oxidative
phosphorylation pathway also has high enzyme costs, leading to a
sub-optimal ATP production strategy, as it has lower production rates
than glycolysis [16]. (vi) Metabolic adaptation to fast proliferation - it
was argued that as opposed to metabolism in differentiated cells that
is geared towards efficient ATP production, the aerobic glycolysis
observed in cancer cells is adapted to facilitate biomass accumulation
and high proliferation. Accordingly, in order to satisfy the require-
ments of anabolic metabolism in addition to the production of ATP,
nutrients must be used to generate both the carbon building blocks of
macromolecules and the reducing power needed for biosynthesis
[17].
Previous computational investigations of the Warburg effect
studied the role of either energy or biomass production in causing
the Warburg effect, focusing solely on central carbon metabolism.
For example, the study of Vander Heiden et al. manually
computed the metabolic requirements for producing one essential
biomass precursor, palmitate (a major constituent of cellular
membranes) considering the stoichiometry of a few central
metabolic pathways. They found that aerobic glycolysis enables
maximal palmitate production yield due to specific reducing
power requirements. In another recent study, Vazquez et al.
employed a schematic model of ATP production in human cells
(considering two lumped reactions representing aerobic glycolysis
and oxidative phosphorylation), elegantly showing that a switch to
aerobic glycolysis should result from cellular maximization of ATP
production [18]. Their schematic model accounts not only for the
stoichiometry of glycolysis and oxidative phosphyrylation but also
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latter bounded by the total cellular solvent capacity, also known as
a macromolecular crowding constraint [19]). A similar approach was
previously employed in the study of over-flow metabolism in E. coli
[20,21]. Another interesting theory explaining overflow metabo-
lism was suggested by Molenaar et al., where the production costs
of the metabolic enzymes involved were accounted for in a self-
replicating model [16].
In this paper, we study the causes of the Warburg effect by
accounting for both energy production and anabolism of essential
biomass constituents, in a genome-scale stoichiometric network
model [22] employing enzyme solvent capacity constraints. The
usage of a large-scale metabolic network is essential if one aims to
correctly account for the inter-connectivity of pathways that
produce the various energy and biomass precursors required for
proliferation, rather than examining just single factors in isolation,
as has been previously performed in [17,18]. Towards this goal,
we rely on a constraint-based modeling (CBM) framework that
serves to analyze the function of metabolic networks by solely
relying on simple physical-chemical constraints [23]. CBM has
already been successfully used in the past to predict the metabolic
state of various microorganisms [24,25], and recently for studying
human cellular metabolism [22]. The potential clinical utility of
the human CBM model was previously demonstrated by its ability
to identify functionally related sets of reactions that are causally
related to hemolytic anemia, and potential drug targets for treating
hypercholesterolemia [22], to predict metabolic biomarkers in
inborn errors of metabolism [26] and to predict a variety of
metabolic behaviors of different human tissues, including the
brain, liver, kidney and more [27,28]. Our analysis shows that
while strictly stoichiometric considerations are insufficient for
explaining the Warburg effect, the incorporation of enzyme
solvent capacity constraints successfully predicts the emergence of
the Warburg effect. The analysis is shown to accurately predict an
experimentally observed metabolic trajectory occurring during
oncogenic progression, as well as the preference of cancer cells for
a high rate of glutamine uptake.
Results
Metabolic requirements of cellular proliferation subject
to enzyme solvent capacity constraints lead to the
Warburg effect
We utilized a genome-scale human metabolic network that includes
3,742 reactions [22], adding a pseudo biomass reaction that represents the
production of a pre-defined set of essential biomass precursors required
for cellular proliferation, as conventionally done in Flux Balance
Analysis (FBA, [29], see Methods). The biomass precursors include
amino-acids, nucleotides, deoxy-nucleotides, ATP, lipids, etc (based on
prior knowledge of their relative concentrations; Methods). In our
simulations, we assume a minimal growth medium with glucose as a
carbon source, as glucose is known to serve as a major fuel in cancer
cells (below and in Text S1 we show that qualitatively similar results
were obtained when considering also the presence of an additional
major nutrient taken by cancer cells, glutamine).
To predict plausible metabolic fluxes in cancer, we first employed a
standard FBA method to identify a feasible flux distribution that
satisfies stoichiometric mass-balance, while maximizing biomass
production yield (see Methods). We found that the predicted flux
distribution does not display the prime characteristic of the Warburg
effect, i.e. lactate secretion (see also Text S1). Interestingly, this finding is
in accordance with a previous study showing a conceptually similar
failure of FBA to predict the Crabtree effect in yeast, in which glucose is
fermented into ethanol under aerobic conditions [30]. Thus,
stoichiometric considerations alone are insufficient for explaining the
Warburg effect and its relation to the metabolic requirements of highly
proliferating cells. Notably, these results stand in difference from those
presented by Vander Heiden et al. [17], claiming that strictly
stoichiometric considerations directly lead to the Warburg effect due
to metabolic demands for cellular proliferation.
A strictly stoichiometric analysis, such as the one presented above,
implicitly assumes that metabolic flux rates can be tuned to achieve
high biomass production yields, without considering constraints
imposed by enzyme concentrations and catalytic rates, which are
prime determinants of metabolic flux. Specifically, while cells might be
free to regulate enzyme concentrations according to metabolic
demands [17], the total enzymes’ concentration in the proliferating
cells is bounded by the cell’s solvent capacity, quantifying the
maximum amount ofmacromolecules that can occupy the intracellular
space [18]. To account for the functional effects of this additional
fundamental constraint, we follow [18,21] and extend our stoichio-
metric genome-scale CBM analysis to compute for each enzyme the
concentration required to facilitate the predicted flux, utilizing data on
known human enzyme catalytic rates (taken from the literature; see
Methods). This modeling approach enables the prediction of metabolic
flux distributions that maximize the biomass production rate and
concomitantly obey the solvent capacity constraints – rather than
predicting flux distributions that only maximize the biomass
production yield as done in standard FBA.
We applied the approach described above (FBA with solvent
capacity constraint) to predict human cellular flux distributions that
maximize the biomass production rate. To simulate varying growth
rates we performed the optimization across a wide range of different
glucose uptake rates. Indeed, under these combined sets of constraints
we find that biomass yield does decline at high growth rates – in
accordance with the Warburg effect [17]; Figure 1a). Specifically, the
predicted metabolic behavior manifests three distinct growth phases
(Figure 1b): (i) optimal yield metabolism at a growth rate that is below 43%
of the maximal possible rate, characterized by low glycolytic vs. high
oxidative phosphorylation (OXPHOS) flux (Figure 2a, phase I), with
low oxygen uptake rates (Figure 1b, phase I). (ii) Intermediate yield
metabolism at growth rate between 43-92%, characterized by increased
glycolytic and oxidative phosphorylation flux (Figure 1a, phase II), the
latter involving a significantly increased oxygen consumption
(Figure 1b, phase II). Notably, our prediction for an intermediate
phase, involving increased oxygen consumption, presents a remarkable
resemblance to two recent experimental studies examining the
metabolic activity at different oncogenic progression stages ([31],
Figure 1c and [32], Figure 2b). Neither the stoichiometric model [17]
nor an analysis using the schematic model of [18] give rise to similar
Author Summary
Cancer cells, as opposed to normal cells, produce a
substantial amount of energy inefficiently via aerobic
glycolysis, even in the presence of sufficient oxygen to
support mitochondrial respiration. Despite the fact that
this phenomenon, called the Warburg effect, has already
been discovered back in 1924, its causes remain poorly
understood. Here we utilize a genome-scale human
metabolic network model and show that by accounting
for cellular capacity for metabolic enzymes, the Warburg
effect is a direct consequence of cancer cells’ adaptation to
fast proliferation. We demonstrate that our model
accurately captures several metabolic phenotypes ob-
served experimentally during cancer development, as well
as the preference of cancer cells to glutamine uptake over
other amino acids.
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maximal possible growth rate, characterized by a sharp increase in
glycolytic flux and a decrease in oxidative phosphorylation (and hence
of O2 uptake). The increase in aerobic glycolysis flux (Figure 2a, phase
III) leads to a rise in lactate secretion rates - a prime characteristic of the
Warburg effect (Figure 1b, phase III).
To further validate the plausibility of the model, we examined the
correlation between its enzyme concentration predictions (based on
predicted flux distributions; see Methods) and mRNA expression
values measured for 1,269 metabolic genes across 60 cancer cell
lines of the NCI-collection [33]. The enzyme concentrations
predicted with FBA accounting for the solvent capacity constraint
show significant rank correlations with the gene expression data
across the different cancer cell-lines (mean Spearman correlation of
0.28, mean p-value = 6.5e221). Notably, the strictly stoichiometric
analysis provides significantly lower correlations with the expression
measurements (with a mean correlation of 0.1; Wilcoxon p-value =
3.5e221), further demonstrating the advantage of the genome-scale
approach that accounts for enzyme solvent capacity.
Explaining the shift to aerobic glycolysis under high
proliferation rates
The shift towards low yield metabolism at high growth rates can be
intuitively explained considering, on one hand, a flux distribution
A with high growth yield (YA) and high ‘cost’ in terms of the
required enzyme concentrations per unit of glucose uptake (CA),
and, on the other hand, a flux distribution B with a lower growth
yield (YB) and lower cost (CB). Considering a bound on the total
enzyme concentration cost, one can observe that when the glucose
uptake is unlimited flux distribution B will provide a higher growth
rate if its growth yield normalized by its cost is higher than that of
flux distribution A (i.e.
YA
CA
v
YB
CB
; Figure 3). When the glucose
uptake rate is limited, maximal growth rate is achieved solely via
flux distribution A or by a combination of A and B.
Concretely, analyzing the results of our model, flux distribution
A stands for a typical metabolic state in phase I, which is
characterized by high mitochondrial oxidative phosphorylation,
with a high growth yield of 0.094 and a high cost of 0.302 (with a
yield to cost ratio of 0.31). Flux distribution B stands for a typical
metabolic state at phase III, which involves a high rate of aerobic
glycolysis, with a low growth yield of 0.035 and a low cost of 0.050
(yield to cost ratio = 0.7). These values indeed transcribe to a
higher growth yield per unit of concentration cost of the enzymes
participating in B, as alluded above. Figure 3 shows that, indeed,
at low growth rates the glucose uptake rate is the sole limiting
factor and hence the high yield oxidative phosphorylation route is
taken; in contrast, at higher growth rates, the enzyme concentra-
tion constraint takes effect, and mixed solutions involving lactate
secretion are necessarily formed. Notably, the predicted flux
distributions across the range of growth rates described in this
paper cannot be obtained from linear combinations of just two
states (as in the above simplified example), but are rather
composed of multiple flux distributions with different growth
yields per concentration cost (as evident for example by the non-
linear curve showing the predicted oxygen uptake rates across
growth rates; Figure 1b). Thus, the flux distributions actually
obtained in genome-scale models markedly differ from those that
can be captured by a simplified analysis that describes the
transition between just two metabolic states with different growth
yields as above, or as in a previous study of Vazquez et al. [18].
Metabolic adaptation to fast proliferation leads to a
preference to high glutamine uptake rates
The role of glutamine in cancer has been a topic of major
interest as cancer cells are known to have a significant high
glutamine uptake rate [34]. Repeating the previous analyses in the
Figure 1. Metabolic behavior across increasing growth rates.
(A) Predicted maximalgrowth yield of human cells (per unit of glucose
uptake; y-axis) for a range of growth rates (x-axis), based strictly on
reactions’ stoichiometry (dotted) and by considering also enzyme mass
and enzyme solvent capacity (solid). Vertical dashed lines indicate the
borders between: phase I (high yield, no lactate secretion), phase II
(medium yield, increased oxidative phosphorylation) and phase III (low
yield, lactate secretion). (B) Predicted lactate secretion flux (red lines)
and oxygen consumption flux (blue lines) for a range of growth rates.
Growth rates were manipulated by varying the glucose uptake rate limit
from 0 until the uptake value needed to reach the maximal growth rate.
Fluxes were normalized by the glucose uptake rate. (C) Experimentally
determined lactate secretion rates (red; squares) and oxygen uptake
rates (blue; circles) during tumor development of H-RasV12/E1A
transformed fibroblasts. NRFU: Normalized relative fluorescence units;
see [31] for more details.
doi:10.1371/journal.pcbi.1002018.g001
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qualitatively similar results to those described above. However, as
expected, the addition of glutamine yields a higher maximal
biomass production rate than the one obtained when only glucose
was available in the medium (Text S1). To investigate the
preference of cancer cells specifically to glutamine over other
Figure 2. Pathway activity differences. (A) as predicted across phases I-III in the model and (B) based on experimental measurements taken from
BJ fibroblast cell lines representing the path towards tumorigenic conversion (CL1-CL4; [32]). The model’s predictions are compatible with the
experimental evidences for increased glycolytic activity (expressed by increased lactate production) during full cancerous development (phase III,
CL4) preceded by an increase in the oxidative phosphorylation (OXPHOS) activity (expressed by the mitochondrial gene expression). Experimental
results for CL2-CL4 are given as the fold change relative to the same measurement in the CL1 cell line. In (B), the bars represent the mean fold change
for each set of metabolites/genes and the error bars represent the standard deviation.
doi:10.1371/journal.pcbi.1002018.g002
Figure 3. A plane describing the feasible region in our model. The axes (A, B) describe the growth rate obtained from flux distributions A and
B, respectively. Thebluelinesrepresenttwodifferentconstraintsontheglucoseuptakerate,andtheredlinerepresentsthemaximalconcentrationconstraint.
Green dashed lines are the contours of the growth rate maximization objective function – the further the line is from the origin, the higher the growth rate.
When the glucose uptake U is limiting (dark grey feasible region), the maximal growth rate is obtained via A only (Solution 1; left green diamond). When both
the uptake and the enzyme concentration constraints are limiting (light grey feasible region), maximal growth rate (G) is obtained via a combination of A and B
(Solution 2; right green diamond), resulting in a shift to a less efficient metabolism and lactate secretion. This can be explained by the fact that the slope of the
g r o w t h - r a t e( m i d d l eg r e e n )l i n e( - 1 )i sl a r g e rt h a nt h eslope of the enzyme concentration limit (red) line ({
YA=CA
YB=CB
), that is the yield-to-cost ratio of flux
distribution B is greater than that of flux distribution A (YA=CAvYB=CB).
doi:10.1371/journal.pcbi.1002018.g003
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of each amino-acid separately to biomass production in the human
model that accounts for enzyme solvent capacity constraints
(Methods). We find that, indeed, the contribution of glutamine to
the proliferation rate is markedly higher than that of all other
amino-acids (Figure 4B). We further show that this result is robust
to changing the bound on maximal amino-acid uptake rate, and
that it remains valid across a large number of random samplings of
enzyme turnover rates (Text S1). Repeating this analysis without
accounting for enzyme solvent capacity constraints (i.e. by
considering only the network stoichiometry in the vanilla FBA
model) fails to predict the preference for glutamine (Figure 4A).
We carefully examined the flux distribution obtained with
glutamine in the growth medium (achieving a growth rate of 0.062
1/h) vs. the one obtained with glutamate (growth rate = 0.056 1/h).
Interestingly, when glutamate is present in the medium, a large
quantity of it is transformed into glutamine in an ATP consuming
reaction catalyzed by the enzyme glutamine synthetase (EC 6.3.1.2).
This satisfies the glutamine biomass requirement as well as the
production of nucleotide precursors, among others. When removing
the ATP requirement from this reaction, the growth rate achieved
with glutamate in the medium increases to 0.059 1/h, which explains
50% of the growth rate difference. Notably, while this provides some
intuitive explanation for the predicted preference for glutamine, we
cannot identify a simple explanation for the entire effect due to the
high complexity of the network model employed.
Discussion
Metabolic adaptation to elevated growth requirements during
cancer development has been recently suggested as the possible
cause of the Warburg effect, a long-standing enigma of cancer
metabolism. In this work we rigorously study this hypothesis using
a genome-scale human metabolic model and demonstrate that
stoichiometric considerations solely are insufficient to explain the
shift to inefficient metabolism, in difference from recent claims
[17]. However, integrating these constraints in a genome-scale
model of human metabolism together with a constraint on enzyme
solvent capacity does lead to the emergence of the Warburg effect
at high proliferation rates. Furthermore, it accurately predicts a
three phase metabolic behavior experimentally observed during
oncogenic progression, as well as a marked preference to a high
uptake rate of glutamine.
The importance of enzyme solvent capacity in metabolic
modeling has already been recognized in the earlier work of Beg
et al. [20], where applying such a constraint to the E. coli model
improved phenotypic predictions. In their work, however, Beg
et al. assumed an upper bound on the total cell-volume occupied by
metabolic enzymes, as opposed to the method introduced here
where we assume a bound on the enzyme mass per cell mass (i.e. a
bound on enzyme fractional concentration). In order to account
for enzyme volumes, Beg et al. estimated enzyme volumes by
assuming a uniform specific volume parameter (representing the ratio
between enzyme mass and volume) for all enzymes. Here, we
employed a simpler approach that does not depend on specific
volume estimations, and explicitly constrains the total sum of
enzyme mass. Notably, we further tested the effect of accounting
for volumes instead of masses, and obtained results which are very
similar to those obtained with masses only (Text S1).
In a recent study by Molenaar et al. [16], a metabolic shift at
high growth rates was predicted based on a general self-replicating
model. Another recent work (by Vazquez et al.) already pointed to
Figure 4. Amino-acid growth rate contribution. The increase in proliferation rate achievable by the increased uptake of each of the 20 amino-
acids in addition to glucose (relative to the baseline growth rate achieved when only glucose is available), as predicted by the stoichiometric model
(A) and by the model accounting for the solvent capacity constraint (B). Glutamine uptake (highlighted in yellow) enables to achieve the highest
increase in growth rate according to the solvent capacity model, in agreement with experimental data showing preference for high glutamine uptake
rates in cancer.
doi:10.1371/journal.pcbi.1002018.g004
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Warburg effect [18]. Notably though, the work presented here
provides a marked contribution over both studies: First, both employ
abstract small-scale models. Specifically, the Vazquez et al. work
introduces a schematic model of ATP production in central
metabolism including just a handful of variables. Furthermore,
similarly to the work of Pfeiffer et al., their work does not explicitly
account for the entire biomass composition and the associated energy
requirements. In contrast, here we study a genome-scale biomass
producing human model that, despite the scores of alternative
biomass and energy production pathways existing in the human
network, successfully shows that highly proliferating cells such as
cancer cells are forced to display Warburg related phenotypes at high
growth rates (phase III). Additionally, and in contrast to the small-
scale models, our genome-scale model correctly predicts an
experimentally observed transitional phase (II). Furthermore, on a
mechanistic level, the genome-scale metabolic description provided
by our analysis is significantly correlated with the gene expression
patterns across the wide array of NCI-60 cancer cell-lines (much
stronger than the association displayed by the stoichiometric model
alone), a result which could not have been predicted by the Vazquez
et al. model. Lastly, the model was able to predict the marked
contribution of glutamine to rapid cellular growth. As a further
demonstration of the robustness of our results, we repeated the
analyses using a model accounting for maintenance ATP production,
obtaining qualitatively similar results (Text S1).
While the data on reactions’ stoichiometry is considered
accurate and comprehensive, enzyme kinetic constant data are
noisy and are currently available for only about 15% of the
reactions in the model. In the analysis presented here, we
addressed this problem by assigning enzymes with missing
turnover rates with the median rate computed over the set of
known turnover rates. Notably, the model’s main findings are
robust to random sampling of turnover rates from a distribution of
known rates, as shown in Text S1. However, repeating the analysis
when assigning all reactions in the model with the median turn-
over rate shows no Warburg characteristics - testifying to the
importance of utilizing known turnover rates even if this data is
sparse. Future measurements of additional enzyme turnover rates
and improved methods for accurately predicting these parameters
(e.g. [35]) are expected to further refine the predictions of cancer
metabolic phenotypes using stoichiometric metabolic models with
an enzyme solvent capacity constraint.
In our work we accounted for a solvent capacity constraint
assuming a limited protein mass per cell, without considering the
effect of enzymes’ sub-cellular compartmentalization. To investi-
gate how the latter would affect our predictions, we repeated the
analysis while considering separate solvent capacity constraints for
cytoplasm and mitochondria (Text S1), yielding quantitatively
similar results to those described above. The incorporation of
solvent capacity constraints for different cellular compartments
may lead to further improved prediction accuracy in the future,
when additional data on enzyme turnover rates becomes available.
Specifically, the addition of membrane-specific constraints may be
a promising direction, as many metabolically important proteins
are confined to membranes (e.g. those of respiratory chain and
membrane biosynthesis).
The presented modeling approach is likely to contribute to
more accurate metabolic modeling of highly proliferating human
cells in general (as was already shown regarding genome-scale
models of microorganisms [21]) and of cancer cells. The latter may
be in turn utilized for anti-cancer drug target prediction and
specifically, for predicting drugs that work to reverse the Warburg
effect. While the current analysis has relied on the available
human generic model, future studies may utilize a similar
methodology in modeling the metabolism of specific cancers.
These may be generated by integrating cancer-signature expres-
sion data with the generic human model to carve out different
cancer types models (using methods such as those outlined in [27]
or [28]), and thus further advance the development of anti-cancer
drugs specific to different cancers.
Materials and Methods
Modeling biomass production using a stoichiometric
model
The Duarte et al. [22] human genome-scale metabolic model,
accounting for 1,496 ORFs, 3,742 reactions and 2,766 metabo-
lites, was used. The metabolic network is represented in a m|n
stoichiometric matrix S, where m is the number of metabolites, n is
the number of reactions, and Sij represents the stoichiometric
coefficient of metabolite i in reaction j. Biomass production was
modeled by adding a new growth reaction to the human model:
this reaction was compiled using the steady state concentrations of
30 biomass compounds including amino acids (0.78 g/gDW;
[36,37]), nucleotides (0.06 g/gDW; [38]), lipids (0.16 g/gDW;
[39]) as well as the growth-associated energy requirement
(24 mmol/gDW of ATP; [40]). Essential amino acids were not
accounted for since they were assumed not to take active part in
the metabolic model besides flowing directly into the biomass
reaction. The full list of biomass metabolites and their relative
concentrations is available in Dataset S1. The biomass reaction
was defined as the objective function of the CBM method Flux
Balance Analysis (FBA; [29]). FBA looks for a flux distribution v
that maximizes the objective function (Equation 1) subject to
steady-state, thermodynamic and growth medium constraints:
maxvbiomass
subject to
ð1Þ
S:v~0 ð2Þ
vminƒvƒvmax ð3Þ
Equation 2 imposes the steady state constraints on the system,
assuming that the metabolite concentrations remain constant in
time. Thermodynamic constraints determining the reaction
directionalities are accounted for via the flux limits vmin and
vmax in Equation 3. The uptake and secretion of a pre-defined set
of metabolites from and to the environment is facilitated via the
definition of exchange reactions in the stoichiometric matrix. The
growth medium is defined via an upper bound on the glucose
uptake exchange reaction (as the carbon source) and by allowing
an unlimited uptake flux of oxygen, sodium, potassium, calcium,
iron, chlorine, phosphate, sulfate and ammonia (based on the
RPMI- 1640 medium definition; as none of these substances can
be used as a carbon source). Growth yield (growth rate divided by
the glucose uptake rate), oxygen uptake and lactate secretion rates
were computed under a wide range of glucose uptake rates
(varying from 0 to 1.55 umol/mgDW/h, the uptake achieving
maximal growth rate) using Flux Variability Analysis (FVA) [41],
allowing us to determine minimal and maximal flux bounds on the
reactions of interest.
Metabolic Modeling Explains the Warburn Effect
PLoS Computational Biology | www.ploscompbiol.org 6 March 2011 | Volume 7 | Issue 3 | e1002018Accounting for enzyme solvent capacity
A constraint on the total enzyme concentration was added to
the biomass production FBA model:
X N
i~1
MWivi
kcati
ƒC
The enzyme mass (per mg dry weight (DW) of cells) required to
maintain the flux in the i-th reaction (vi [mmol/(mgDW*h)]) is given
by the product of vi and the enzyme’s molecular weight (MWi [mg/
mmol]) divided by its turnover number (kcati [1/h]) [21]. The limit on
the total metabolic enzyme mass (C=0.078 [mg/mgDW]) was
estimated based on dry cell weight protein biomass measurements
(0.779 [mg/mgDW]; [42]) multiplied by the fraction of metabolic
genes out of the total cellular protein mass, which was evaluated as the
sum of metabolic gene expression readouts divided by the total sum of
gene expression readouts ([33]; equal to 0.1). Notably, the reliability of
this value was validated based on a recently published protein
abundance dataset ([43], Text S1). In order to account for positive
fluxes only, each bidirectional reaction was split into two unidirec-
tional reactions, resulting in a total of 4,894 reactions. Enzyme
molecular weights were obtained from the BRENDA database ([44];
Dataset S2) while turnover number data was taken from BRENDA
and from the SABIO-RK databases ([45]; Dataset S3), and assigned
as following: each reaction with a known Enzyme Commission (EC)
number was queried against BRENDA for the maximal human wild-
type kcat value. In case a human kcat value was not available, the
maximal non-human wild-type turnover number was assigned. In
case BRENDA data was not available, the SABIO-RK database was
used in a similar manner. As a result, 729 reactions were assigned with
kcat values while the other 4,165 reactions were assigned with the
median kcat value across the set of known kcat values (25 1/s).
Pathway activity analysis
Flux distributions were computed under maximal growth rates
in the three growth phases (phase I – 0.0243 1/h; phase II –
0.0515 1/h; phase III – 0.0557 1/h). For each phase, the median
flux distribution across 1000 different uniform samples was
calculated using ACHR sampling [46]. Mean pathway flux was
calculated as the mean flux across the reactions belonging to the
pathway of interest. Data on relative metabolomic measurements
for lactate, and on relative transcriptomic measurements for genes
which are important for mitochondrial biogenesis (PGC-1-a,
NRF-1, TFAM and ATP5E) was taken from [32].
Correlation with gene expression data
Gene expression readouts for 1,269 metabolic genes across 60
cell lines from the NCI-60 collection [33] were correlated with
enzyme concentrations predicted by (i) a stoichiometric only
model and by (ii) a model accounting also for enzyme solvent
capacity. Given a flux distribution vector v, for each reaction i, the
enzyme concentration ½e i needed to maintain its flux vi (the i-th
entry in v) was calculated as the product ofviand the molecular
weight of the enzyme catalyzing this reaction (denoted MWi),
divided by its turnover number (denoted kcati), that is,
½e i~
MWi
kcati vi. Total enzyme concentrations (per gene) were given
by summing the enzyme concentrations across all of the reactions
associated with the gene of interest (i.e. reactions catalyzed by
enzymes encoded by this gene), based on a gene-to-reaction
mapping given in the human metabolic model. The Spearman
correlation between the gene expression vector and inferred
enzyme concentration vector was calculated for the two models in
each of the 60 cell lines. The robustness of the results was validated
against 1,000 uniformly sampled flux distributions from the
solution spaces of the two models using ACHR sampling [46].
Modeling amino-acid uptakes
Each of the 20 amino acids was added, in turn, to the growth media,
resulting in 20 different maximal biomass production rates calculated
based on (i) the stoichiometric model, and on (ii) a model additionally
accounting for the solvent capacity constraint. The maximal amino-
acid uptake rate was set to the same uptake rate as glucose; the results
are shown to be robust to the choice of this value (Text S1).
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